Overview

A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis

Status:
Not yet recruiting
Trial end date:
2023-03-14
Target enrollment:
Participant gender:
Summary
This study is a proof-of-concept study to demonstrate if a daily dose of a 2-days pre-treatment of Fexofenadine 180mg is effective in alleviating the AR symptoms and to assess the additional benefit to the patient in terms of preventing Allergic Rhinitis (AR) symptoms. The total study duration per participant is expected at least 4 months, depending on the timing of the screening visit. 5 visits are planned, screening, confirmation inclusion challenge, randomization visit, challenge and end of study visit.
Phase:
Phase 3
Details
Lead Sponsor:
Opella Healthcare Group SAS, a Sanofi Company
Treatments:
Fexofenadine